PMID- 7525655
OWN - NLM
STAT- MEDLINE
DCOM- 19941202
LR  - 20181113
IS  - 0021-9738 (Print)
IS  - 0021-9738 (Linking)
VI  - 94
IP  - 5
DP  - 1994 Nov
TI  - Recombinant soluble form of the human high-affinity immunoglobulin E (IgE) 
      receptor inhibits IgE production through its specific binding to IgE-bearing B 
      cells.
PG  - 2162-5
AB  - A recombinant soluble form of the alpha subunit of the human high-affinity 
      receptor for IgE (rsFc epsilon RI alpha), one of the potent IgE-binding 
      molecules, was tested for its ability to regulate IL-4-induced IgE synthesis by 
      human lymphocytes. Addition of rsFc epsilon RI alpha to cultures induced a 
      dose-dependent inhibition of the T cell-dependent and independent synthesis of 
      IgE. The suppression of IgE synthesis was observed at the protein and the mRNA 
      levels, and it was IgE class specific. By flow cytometry, specific binding of 
      rsFc epsilon RI alpha was detected on surface IgE-bearing B cells as well as on 
      U266 cells, and it was completely blocked by preincubation with IgE. rsFc epsilon 
      RI alpha bound to the cell surface IgE could be effectively dissociated not only 
      by a large excess of IgE, but also by an anti-rsFc epsilon RI alpha mAb that 
      competes with IgE for the binding to rsFc epsilon RI alpha. This mAb abolished 
      the rsFc epsilon RI alpha-mediated suppression of IgE synthesis. These data 
      suggest that rsFc epsilon RI alpha may have a function in selectively suppressing 
      IgE synthesis through its interaction with the membrane-bound form of IgE.
FAU - Yanagihara, Y
AU  - Yanagihara Y
AD  - Clinical Research Center for Allergy, National Sagamihara Hospital, Kanagawa, 
      Japan.
FAU - Kajiwara, K
AU  - Kajiwara K
FAU - Ikizawa, K
AU  - Ikizawa K
FAU - Koshio, T
AU  - Koshio T
FAU - Okumura, K
AU  - Okumura K
FAU - Ra, C
AU  - Ra C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, Differentiation, B-Lymphocyte)
RN  - 0 (CD40 Antigens)
RN  - 0 (Receptors, IgE)
RN  - 0 (Recombinant Proteins)
RN  - 207137-56-2 (Interleukin-4)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Adult
MH  - Antibodies, Monoclonal/immunology
MH  - Antigens, CD/physiology
MH  - Antigens, Differentiation, B-Lymphocyte/physiology
MH  - B-Lymphocytes/*immunology
MH  - CD40 Antigens
MH  - Cells, Cultured
MH  - Humans
MH  - Immunoglobulin E/analysis/*biosynthesis
MH  - Interleukin-4/pharmacology
MH  - Receptors, IgE/*physiology
MH  - Recombinant Proteins/pharmacology
PMC - PMC294671
EDAT- 1994/11/01 00:00
MHDA- 1994/11/01 00:01
PMCR- 1994/11/01
CRDT- 1994/11/01 00:00
PHST- 1994/11/01 00:00 [pubmed]
PHST- 1994/11/01 00:01 [medline]
PHST- 1994/11/01 00:00 [entrez]
PHST- 1994/11/01 00:00 [pmc-release]
AID - 10.1172/JCI117574 [doi]
PST - ppublish
SO  - J Clin Invest. 1994 Nov;94(5):2162-5. doi: 10.1172/JCI117574.